On October 8, 2026, the FDA approved atezolizumab (Tecentriq) plus chemotherapy after surgery for stage III colon cancer with deficient mismatch repair (dMMR). In the ATOMIC trial, the combination cut the risk of the cancer coming back or death by 50%. Here is what the news means for patients and caregivers, in plain language.